Exact Mass: 459.1981
Exact Mass Matches: 459.1981
Found 161 metabolites which its exact mass value is equals to given mass value 459.1981
,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
Hytrin
C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C72900 - Adrenergic Antagonist D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D018674 - Adrenergic Antagonists D000089162 - Genitourinary Agents > D064804 - Urological Agents Terazosin hydrochloride dihydrate is a quinazoline derivative and a competitive and orally active α1-adrenoceptor antagonist. Terazosin hydrochloride dihydrate works by relaxing blood vessels and the opening of the bladder. Terazosin hydrochloride dihydrate has the potential for benign prostatic hyperplasia (BPH) and high blood pressure treatment[1][2][3].
Apixaban
B - Blood and blood forming organs > B01 - Antithrombotic agents > B01A - Antithrombotic agents > B01AF - Direct factor xa inhibitors C78275 - Agent Affecting Blood or Body Fluid > C263 - Anticoagulant Agent > C173067 - Direct Factor Xa Inhibitor C78275 - Agent Affecting Blood or Body Fluid > C263 - Anticoagulant Agent > C180619 - Direct Oral Anticoagulant D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors > D015842 - Serine Proteinase Inhibitors D006401 - Hematologic Agents > D000925 - Anticoagulants > D000991 - Antithrombins COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
2-[(1S,2S,4R)-2-Hydroxy-7,7-dimethyl-1-(spiro[indene-1,4'-piperidine]-1'-ylsulfonylmethyl)-2-bicyclo[2.2.1]heptanyl]acetic acid
Apixaban
B - Blood and blood forming organs > B01 - Antithrombotic agents > B01A - Antithrombotic agents > B01AF - Direct factor xa inhibitors C78275 - Agent Affecting Blood or Body Fluid > C263 - Anticoagulant Agent > C173067 - Direct Factor Xa Inhibitor C78275 - Agent Affecting Blood or Body Fluid > C263 - Anticoagulant Agent > C180619 - Direct Oral Anticoagulant D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors > D015842 - Serine Proteinase Inhibitors D006401 - Hematologic Agents > D000925 - Anticoagulants > D000991 - Antithrombins COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
6-{[6-(2-Dimethylamino-aethyl)-4-methoxy-benzo[1,3]dioxol-5-yl]-acetyl}-2,3-dimethoxy-benzoesaeure-methylester|6-{[6-(2-dimethylamino-ethyl)-4-methoxy-benzo[1,3]dioxol-5-yl]-acetyl}-2,3-dimethoxy-benzoic acid methyl ester|longicine|narceine methyl ester
rel-(5aR,6R,12S,14aR)-12-[(1R)-1,2-dihydroxy-2-methylpropyl]-1,2,3,5a,6,11,12,14a-octahydro-5a-hydroxy-6,9-dimethoxy-5H,14H-pyrrolo[1,2:4,5]pyrazino[1,2:1,6]pyrido[3,4-b]indole-5,14-dione|rel-(8S,19S)-19,20-dihydro-9,19,20-trihydroxy-8-methoxy-9-epi-fumitremorgin C
Ala Asn Gln Gln
Ala Gln Asn Gln
Ala Gln Gln Asn
Asp Pro Gln Thr
Asp Pro Thr Gln
Asp Gln Pro Thr
Asp Gln Thr Pro
Asp Thr Pro Gln
Asp Thr Gln Pro
Glu Asn Pro Thr
Glu Asn Thr Pro
Glu Pro Asn Thr
Glu Pro Gln Ser
Glu Pro Ser Gln
Glu Pro Thr Asn
Glu Gln Pro Ser
Glu Gln Ser Pro
Glu Ser Pro Gln
Glu Ser Gln Pro
Glu Thr Asn Pro
Glu Thr Pro Asn
Gly Gln Gln Gln
Asn Ala Gln Gln
Asn Glu Pro Thr
Asn Glu Thr Pro
Asn Asn Asn Val
Asn Asn Val Asn
Asn Pro Glu Thr
Asn Pro Thr Glu
Asn Gln Ala Gln
Asn Gln Gln Ala
Asn Thr Glu Pro
Asn Thr Pro Glu
Asn Val Asn Asn
Pro Asp Gln Thr
Pro Asp Thr Gln
Pro Glu Asn Thr
Pro Glu Gln Ser
Pro Glu Ser Gln
Pro Glu Thr Asn
Pro Asn Glu Thr
Pro Asn Thr Glu
Pro Gln Asp Thr
Pro Gln Glu Ser
Pro Gln Ser Glu
Pro Gln Thr Asp
Pro Ser Glu Gln
Pro Ser Gln Glu
Pro Thr Asp Gln
Pro Thr Glu Asn
Pro Thr Asn Glu
Pro Thr Gln Asp
Gln Ala Asn Gln
Gln Ala Gln Asn
Gln Asp Pro Thr
Gln Asp Thr Pro
Gln Glu Pro Ser
Gln Glu Ser Pro
Gln Gly Gln Gln
Gln Asn Ala Gln
Gln Asn Gln Ala
Gln Pro Asp Thr
Gln Pro Glu Ser
Gln Pro Ser Glu
Gln Pro Thr Asp
Gln Gln Ala Asn
Gln Gln Gly Gln
Gln Gln Asn Ala
Gln Gln Gln Gly
Gln Ser Glu Pro
Gln Ser Pro Glu
Gln Thr Asp Pro
Gln Thr Pro Asp
Ser Glu Pro Gln
Ser Glu Gln Pro
Ser Pro Glu Gln
Ser Pro Gln Glu
Ser Gln Glu Pro
Ser Gln Pro Glu
Thr Asp Pro Gln
Thr Asp Gln Pro
Thr Glu Asn Pro
Thr Glu Pro Asn
Thr Asn Glu Pro
Thr Asn Pro Glu
Thr Pro Asp Gln
Thr Pro Glu Asn
Thr Pro Asn Glu
Thr Pro Gln Asp
Thr Gln Asp Pro
Thr Gln Pro Asp
Val Asn Asn Asn
2-(2-ethoxy-5-piperidin-1-ylsulfonylphenyl)-5-methyl-7-propyl-1H-imidazo[5,1-f][1,2,4]triazin-4-one
(3S,4S)-TERT-BUTYL 3-ETHOXY-4-(2-(3-(TRIFLUOROMETHYL)BENZAMIDO)ACETAMIDO)PYRROLIDINE-1-CARBOXYLATE
A-D-GLUCOPYRANOSIDE,METHYL2-DEOXY-2-[[(PHENYLMETHOXY)CARBONYL]AMINO]-3-O-(PHENYLMETHYL)-,6-ACETATE
Fluazacort
C147908 - Hormone Therapy Agent > C548 - Therapeutic Hormone > C1636 - Therapeutic Steroid Hormone C308 - Immunotherapeutic Agent > C574 - Immunosuppressant > C211 - Therapeutic Corticosteroid
1-[(4-fluorophenyl)methyl]-N-[4-(4-methyl-1-piperazinyl)phenyl]-2-oxo-3H-benzimidazole-5-carboxamide
(6R,7R,8R)-N-(3-fluorophenyl)-8-(hydroxymethyl)-7-[4-(2-methylphenyl)phenyl]-2-oxo-1,4-diazabicyclo[4.2.0]octane-4-carboxamide
6,7-Dimethoxy-2-[4-(tetrahydrofuran-2-ylcarbonyl)piperazin-1-yl]quinazolin-4-amine hydrochloride dihydrate
1-(2,5-difluorophenyl)-3-[(2R,3S,6R)-6-[2-(3,4-dihydro-1H-isoquinolin-2-yl)-2-oxoethyl]-2-(hydroxymethyl)oxan-3-yl]urea
1-(2,5-difluorophenyl)-3-[(2S,3R,6S)-6-[2-(3,4-dihydro-1H-isoquinolin-2-yl)-2-oxoethyl]-2-(hydroxymethyl)oxan-3-yl]urea
1-(2,5-difluorophenyl)-3-[(2S,3R,6R)-6-[2-(3,4-dihydro-1H-isoquinolin-2-yl)-2-oxoethyl]-2-(hydroxymethyl)-3-oxanyl]urea
1-(2,5-difluorophenyl)-3-[(2S,3S,6R)-6-[2-(3,4-dihydro-1H-isoquinolin-2-yl)-2-oxoethyl]-2-(hydroxymethyl)-3-oxanyl]urea
1-(2,5-difluorophenyl)-3-[(2R,3S,6S)-6-[2-(3,4-dihydro-1H-isoquinolin-2-yl)-2-oxoethyl]-2-(hydroxymethyl)-3-oxanyl]urea
1-(2,5-difluorophenyl)-3-[(2R,3R,6S)-6-[2-(3,4-dihydro-1H-isoquinolin-2-yl)-2-oxoethyl]-2-(hydroxymethyl)-3-oxanyl]urea
(2R,3R,3aS,9bS)-2-[3,4-dihydro-1H-isoquinolin-2-yl(oxo)methyl]-7-(2-fluorophenyl)-3-(hydroxymethyl)-1,2,3,3a,4,9b-hexahydropyrrolo[2,3-a]indolizin-6-one
[(1R)-7-methoxy-2-methyl-1-[(1-methyl-4-imidazolyl)sulfonyl]-1-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,4-piperidine]yl]methanol
[(1S)-7-methoxy-2-methyl-1-[(1-methyl-4-imidazolyl)sulfonyl]-1-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,4-piperidine]yl]methanol
(6S,7S,8R)-N-(3-fluorophenyl)-8-(hydroxymethyl)-7-[4-(2-methylphenyl)phenyl]-2-oxo-1,4-diazabicyclo[4.2.0]octane-4-carboxamide
1-(2,5-difluorophenyl)-3-[(2S,3S,6S)-6-[2-(3,4-dihydro-1H-isoquinolin-2-yl)-2-oxoethyl]-2-(hydroxymethyl)-3-oxanyl]urea
1-(2,5-difluorophenyl)-3-[(2R,3R,6R)-6-[2-(3,4-dihydro-1H-isoquinolin-2-yl)-2-oxoethyl]-2-(hydroxymethyl)-3-oxanyl]urea
(2S,3S,3aR,9bR)-2-[3,4-dihydro-1H-isoquinolin-2-yl(oxo)methyl]-7-(2-fluorophenyl)-3-(hydroxymethyl)-1,2,3,3a,4,9b-hexahydropyrrolo[2,3-a]indolizin-6-one
(6S,7S,8S)-N-(3-fluorophenyl)-8-(hydroxymethyl)-7-[4-(2-methylphenyl)phenyl]-2-oxo-1,4-diazabicyclo[4.2.0]octane-4-carboxamide
(6R,7R,8S)-N-(3-fluorophenyl)-8-(hydroxymethyl)-7-[4-(2-methylphenyl)phenyl]-2-oxo-1,4-diazabicyclo[4.2.0]octane-4-carboxamide
CZ415
CZ415 is a potent and highly selective mTOR inhibitor with a pIC50 of 8.07. CZ415 inhibits mTORC1 and mTORC2 protein complex. CZ415 is a potent and highly selective mTOR inhibitor with a pIC50 of 8.07. CZ415 inhibits mTORC1 and mTORC2 protein complex.
IDH1 Inhibitor 7
IDH1 Inhibitor 7 (Compound 88) is an IDH1 inhibitor with an IC50 of less than 100 nM[1].